Trimipramine, Serum
Use
This test is useful for monitoring trimipramine concentration during therapy, evaluating potential trimipramine toxicity, and may aid in evaluating patient compliance. Therapeutic ranges are based on serum samples collected at trough (immediately before the next dose). The risk of toxicity increases when concentrations exceed 500 ng/mL.
Special Instructions
The test can not be performed on whole blood. Serum must be separated from cells within 2 hours of collection to prevent falsely elevated levels due to drug release from red blood cells. Specimens from gel tubes are not acceptable as the drug can absorb on the gel, leading to falsely decreased concentrations.
Limitations
Coadministration of fluvoxamine, moclobemide, or quinidine inhibits the metabolism and markedly increases the serum concentrations of trimipramine. Therapeutic ranges are only applicable for specimens collected at trough, and levels may be elevated in non-trough specimens. Interpretation of results should include clinical evaluation, as some individuals may respond well outside of the therapeutic range.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 4083-2
- 4083-2
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Collect specimen immediately before next scheduled dose (minimum 12 hours after last dose). Centrifuge and aliquot serum into a plastic vial. Serum must be separated from cells within 2 hours of collection.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, gel tubes
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 28 days |
| Frozen | 28 days |